Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Current Trends in Immunology   Volumes    Volume 23 
Improving the anti-inflammatory/anti-angiogenic properties of gold nanoparticles in the treatment of experimental rheumatoid arthritis
Nehal E. Abdel-Hakem, Amira S. Abo-El-Atta, Rehab M. Samaka, Mohamed EL-Shahat, Iman H. Bassyouni, Roba M. Talaat
Pages: 33 - 44
Number of pages: 12
Current Trends in Immunology
Volume 23 

Copyright © 2022 Research Trends. All rights reserved

Rheumatoid arthritis (RA) is a chronic autoimmune disease with no apparent cure. There is a continued need for the development of new therapeutic strategies. Nanotechnology has been a proven effective route toward novel and fascinating biomedical applications. The application of gold nanoparticles (AuNPs) in RA treatment is still curious. Thus, this study was designed to evaluate the anti-inflammatory and anti-angiogenic potential of spherical AuNPs with different sizes (5, 25, and 75 nm). Collagen-induced arthritis (CIA) rats were divided into CIA model, AuNP, and methotrexate (MTX)-treated groups. Untreated rats were used as the control group. Pro-inflammatory/anti-inflammatory and angiogenic mediators were measured by enzyme-linked immunosorbent assay (ELISA). A remarkable increase in proinflammatory cytokines [IL-6, IL-17, tumor necrosis factor (TNF-α), and interferon (IFN-γ)] coincides with a remarkable reduction in IL-4, IL-10, and transforming growth factor (TGF-β) anti-inflammatory mediators was observed in the CIA group compared to normal animals. A significant increase in vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) levels was found in the untreated CIA group. Our results confirm the anti-inflammatory properties of AuNPs via downregulating pro-inflammatory (IL-1β, IL-17, IL-23, IL-12, TNF-α, and IFN-γ) and angiogenic mediators (VEGF and PDGF) and increasing anti-inflammatory cytokine (IL-4 and TGF-β) secretion. Our preliminary findings suggest that AuNPs with a diameter of 25 nm could be used as a possible nanotherapeutic agent for RA. In comparison to methotrexate, AuNPs (25 nm) have improved anti-inflammatory/ anti-angiogenic properties in the treatment of experimental rheumatoid arthritis. AuNPs have the potential to be exploited as a novel therapy for RA, bringing a new era in the treatment of autoimmune diseases.
View Full Article  


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms